Skip to content

Tolerance & Responsiveness Improvement for Metformin (TRIM)

Tolerance & Responsiveness Improvement for Metformin (TRIM): Open-label, Parallel-group Randomized Trial, Phase 4

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03670043
Enrollment
29
Registered
2018-09-13
Start date
2019-03-19
Completion date
2021-08-15
Last updated
2021-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type2 Diabetes Mellitus

Brief summary

The overall goal is to explore the hypothesis that prebiotic fiber Psyllium will ameliorate diarrhea in African American men (AAM) with Type2 Diabetes Mellitus (T2D).

Interventions

To evaluate whether Psyllium will alleviate diarrhea

Metformin Extended Release Oral Tablet is standard of care for diarrhea in patients taking metformin

Sponsors

West Side Institute for Science and Education
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
20 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. Male (M) 2. African American (AA) race 3. Age 20-70 years 4. BMI 28-59 kg/m2 5. T2D 6. A1c 6.5 - 8.9% 7. eGFR =/\> 30 8. Drug-naïve or use Glipizide or newly started on Metformin (within 2 weeks).

Exclusion criteria

1. Chronic kidney disease stage 3b, 4 and 5 (eGFR \< 30) 2. Insulin use 3. Oral steroids use (inhalers and creams are allowed) 4. Antibiotic use within the last month 5. Artificial heart valves 6. Hospitalization for chronic condition within 6 months prior to the study 7. History, manifestations or medications of significant metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, urological, neurological, psychiatric/ psychological disorders, or social circumstances which in the opinion of the investigator would be expected to interfere with the study or increase risk to the subject. 8. Use of other antidiabetic drugs (except glipizide and metformin). 9. Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. Additional

Design outcomes

Primary

MeasureTime frameDescription
Birmingham Irritable Bowel Syndrome (IBS) Symptom Questionnaire3 monthsThis scale is based on symptoms that frequently occur in IBS cases, examines abdominal discomfort status, stool properties, and defecation feelings. The scale includes a total of 11 items, with 6 possible grades for each item that range from 0 points (never having this symptom) to 5 points (the symptom is always present). The total score is the sum of the scores for each item. The Total score is used. No subscale is used. Total range is minimum=0, maximum=55. The higher values represent a worse outcome.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026